Hypofractionated Radiation Therapy for Prostate Cancer
Trial Summary
What is the purpose of this trial?
The purpose of this study is to test the safety of a new type of IG-IMRT called "ultra-hypofractionated IG-IMRT" where a higher dose of radiation is given to the tumor during each treatment day. Since higher doses of radiation are used each day, the total number of treatment days needed to complete this type of radiation is only five instead of the 45-48 treatments currently used. Treatment takes place every other day and is complete after 2 weeks. If the patient decides to get this treatment, they will come in for 5 treatments. This is different from the 48 treatments they would get normally.
Research Team
Sean McBride, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Eligibility Criteria
Men aged 18 or older with low to intermediate risk prostate cancer, defined by specific PSA levels, Gleason scores, and clinical stages. They must have a good performance status (able to carry out daily activities), no severe urinary symptoms, a prostate size ≤60 cc, and no evidence of advanced disease on MRI/CT scans.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Hypofractionated, image-guided, intensity-modulated external beam radiation
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Montefiore Medical Center
Collaborator